Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE)
Beijing InnoCare Pharma Tech Co., Ltd.
105 participants
Apr 27, 2026
INTERVENTIONAL
Conditions
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).
Eligibility
Inclusion Criteria8
- Aged ≥18 and ≤75 years.
- Diagnosed with cutaneous lupus erythematosus (CLE) for at least 3 months before the screening visit.
- Biopsy-proven histologically consistent with discoid lupus erythematosus (DLE) and/or subacute cutaneous lupus erythematosus (SCLE).
- CLASI activity (CLASI-A) score ≥8 at both the screening and baseline (Day 1) visits.
- May have concomitant systemic lupus erythematosus (SLE) or not.
- The treatment regimen is stable and can be maintained until the end of the study treatment.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result before the first dose on Day 1.
- Women of childbearing potential (WOCBP) and male subjects must agree to use highly effective contraceptive methods throughout the study treatment period and for one month (28 days) after the last dose
Exclusion Criteria8
- Specific cutaneous lupus erythematosus subtypes: acute cutaneous lupus erythematosus (ACLE), tumid lupus, lupus panniculitis (deep lupus), chilblain lupus.
- Patients with drug-induced cutaneous lupus erythematosus and/or drug-induced systemic lupus erythematosus.
- Subjects with active kidney disease 4．Other inflammatory joint or skin diseases or overlap syndrome not caused by systemic lupus erythematosus (SLE) as the primary disease.
- \. Other autoimmune diseases except for secondary Sjögren's syndrome. 6. Concurrent herpes zoster infection at screening or before dosing on Day 1, or a history of severe herpes zoster or severe herpes simplex infection.
- \. Positive Hepatitis B surface Antigen (HBsAg) at screening; or abnormal Hepatitis B Virus (HBV)Deoxyribonucleic Acid (DNA) Polymerase Chain Reaction (PCR) test result in subjects positive for Hepatitis B core Antibody (HBcAb).
- Evidence of active, latent, or inadequately treated mycobacterium tuberculosis (TB) infection.
- Previous or current use of other immunomodulatory or immunosuppressive treatments except for permitted background medications specified in the protocol.
- \. Inadequate organ function levels, including abnormalities in hematology, liver function, renal function, coagulation function, cardiac function, etc.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive ICP-488 orally as per the protocol
Patients will receive ICP-488 orally as per the protocol
Patients will receive ICP-488 Placebo orally as per the protocol.
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07440537